- Home
- HMST vs BWAY Comparison
HMST vs BWAY Comparison
Compare HMST & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- BWAY
- Stock Information
- Founded
- HMST 1921
- BWAY 2003
- Country
- HMST United States
- BWAY Israel
- Employees
- HMST 819
- BWAY N/A
- Industry
- HMST Major Banks
- BWAY Medical/Dental Instruments
- Sector
- HMST Finance
- BWAY Health Care
- Exchange
- HMST Nasdaq
- BWAY Nasdaq
- Market Cap
- HMST 194.6M
- BWAY 177.4M
- IPO Year
- HMST 2012
- BWAY 2019
- Fundamental
- Price
- HMST $10.32
- BWAY $10.28
- Analyst Decision
- HMST Buy
- BWAY Strong Buy
- Analyst Count
- HMST 2
- BWAY 3
- Target Price
- HMST $14.75
- BWAY $13.17
- AVG Volume (30 Days)
- HMST 176.5K
- BWAY 57.5K
- Earning Date
- HMST 01-27-2025
- BWAY 03-05-2025
- Dividend Yield
- HMST N/A
- BWAY N/A
- EPS Growth
- HMST N/A
- BWAY N/A
- EPS
- HMST N/A
- BWAY 0.04
- Revenue
- HMST $75,702,000.00
- BWAY $38,631,000.00
- Revenue This Year
- HMST N/A
- BWAY $388.82
- Revenue Next Year
- HMST $9.32
- BWAY $18.70
- P/E Ratio
- HMST N/A
- BWAY $128.37
- Revenue Growth
- HMST N/A
- BWAY 34.19
- 52 Week Low
- HMST $8.09
- BWAY $4.61
- 52 Week High
- HMST $16.10
- BWAY $11.25
- Technical
- Relative Strength Index (RSI)
- HMST 47.32
- BWAY 46.35
- Support Level
- HMST $9.61
- BWAY $10.24
- Resistance Level
- HMST $10.58
- BWAY $10.89
- Average True Range (ATR)
- HMST 0.56
- BWAY 0.47
- MACD
- HMST 0.02
- BWAY -0.04
- Stochastic Oscillator
- HMST 53.42
- BWAY 10.34
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.